ARTICLE | Clinical News
Anti-G17 immunogen (formerly Gastrimmune): Began Phase III trial
March 20, 2000 8:00 AM UTC
Aphton Corp. (APHT), Miami, Fla. Product: Anti-G17 immunogen (formerly Gastrimmune) Business: Cancer Therapeutic category: Immune stimulation Target: Gastrin Description: Amino terminus of gastrin-17 ...